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Article
ADHD is a common neuropsychiatric disorder defined by 
a persistent pattern of inattention and/or hyperactivity/
impulsivity that interferes with functioning or develop-
ment (American Psychiatric Association [APA], 2013). 
The first systematic studies of ADHD focused on school-
aged boys (Still, 1902). Later, it was recognized that many 
girls have similar problems, and that symptoms persist 
into adulthood in the majority of cases, with worldwide 
prevalence estimates of ADHD around 2.5% to 3% in the 
adult population (Polanczyk, de Lima, Horta, Biederman, 
& Rohde, 2007; Simon, Czobor, Balint, Meszaros, & 
Bitter, 2009).
In addition to the core clinical symptoms of ADHD, psy-
chiatric and non-psychiatric coexisting problems and clini-
cal conditions have been described in ADHD patients 
(Angold, Costello, & Erkanli, 1999). In particular, psychiat-
ric comorbid conditions are recognized in both children and 
adults, and pose considerable clinical and public health 
challenges (Angold et al., 1999; Halmoy et al., 2010).
Recognition of medical/somatic conditions is also a key 
component in the routine clinical assessment of psychiatric 
patients. Failure to diagnose medical conditions can lead to 
misdiagnosis or incorrect treatment, with potentially seri-
ous consequences. According to the current diagnostic 
criteria for ADHD in the Diagnostic and Statistical Manual 
of Mental Disorders (5th ed.; DSM-5; APA, 2013), the diag-
nosis of ADHD is only considered appropriate if the distur-
bance is not judged to be the direct pathophysiological 
consequence of a specific medical condition (e.g., multiple 
sclerosis, stroke, hypothyroidism). However, in the most 
recent version of the International Classification of Diseases 
and Related Health Problems (ICD-10; World Health 
Organization, 1992), it is also emphasized that psychiatric 
syndromes may be causally related to cerebral and systemic 
diseases, and that proper diagnosis will require two codes: 
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Objective: To systematically review, synthesize, and appraise available evidence, connecting adult ADHD (aADHD) 
with somatic disease. Method: Embase, Psychinfo, and Medline databases were searched for studies published from 
1994 to 2015 addressing aADHD and somatic comorbidity. Somatic conditions were classified according to International 
Classification of Diseases (ICD-10) codes. Levels of evidence were graded as inconclusive, tentative, or well documented. 
Results: Most of the 126 studies included in the qualitative synthesis were small and of modest quality. Obesity, sleep 
disorders, and asthma were well-documented comorbidities in aADHD. Tentative evidence was found for an association 
between aADHD and migraine and celiac disease. In a large health registry study, cardiovascular disease was not associated 
with aADHD. Conclusion: There are few large systematic studies using standardized diagnostic criteria evaluating aADHD 
and somatic comorbidities. Significant associations are found between aADHD and several somatic diseases, and these 
are important to consider when assessing and treating either aADHD or the somatic diseases. (J. of Att. Dis. XXXX; XX(X) 
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one for the psychopathological syndrome and the other for 
the underlying disorder.
Compared with the extensive descriptions of psychiatric 
comorbidity, somatic comorbidity in ADHD has received 
less attention in the research literature, particularly among 
adults. This discrepancy is obvious in the recent diagnostic 
definition of ADHD (APA, 2013), where many psychiatric 
disorders are listed either as possible differential diagnoses 
or as comorbid conditions. The only non-psychiatric disor-
der specifically mentioned is medication-induced symp-
toms of ADHD. Associated medical conditions have been 
studied more in other psychiatric disorders, where they are 
also considered to contribute to a lower quality of life and 
reduced life expectancy. In schizophrenia, it is known that 
weight gain, diabetes, metabolic syndrome, and cardiovas-
cular disease are common, and it is speculated that a shared 
vulnerability for psychosis and medical conditions can 
explain some of this comorbidity (Ringen, Engh, Birkenaes, 
Dieset, & Andreassen, 2014). Population-based prospective 
studies have documented an increased risk of premature 
death and reduced life expectancy also for ADHD patients 
(Dalsgaard, Ostergaard, Leckman, Mortensen, & Pedersen, 
2015), but it is unclear if this risk is mediated by coexisting 
medical diseases.
The primary objective of this review was to obtain an 
overview of, and evaluate, the literature covering this topic 
during the past 20 years. Secondary objectives were to 
inform clinicians on the most common somatic comorbid 
conditions to enhance optimal patient evaluation and treat-
ment, and to identify particular areas of research that should 
be further investigated.
Method
Literature Search Strategies and Data Sources
We performed a systematic review of the literature address-
ing aADHD and somatic comorbidity. The search strategy 
was developed in collaboration with a university librarian 
experienced in systematic medical literature searches. The 
electronic databases Embase, Psychinfo, and Medline were 
searched in December 2014 and January 2015, limiting the 
search to study participants above 18 years of age. The 
search was finalized on January 26, 2015, retrieving 4,091 
papers. The detailed electronic search strategy is provided 
in Supplementary 1.
After removing duplicates and studies published prior to 
1994 when the Diagnostic and Statistical Manual of Mental 
Disorders (4th ed.; DSM-IV; APA, 1994) was introduced, 
J.T.I. screened title and abstract in the remaining studies, 
excluding papers that clearly did not fulfill the inclusion cri-
teria listed below. Furthermore, reference lists of the 
retrieved papers were hand searched to identify additional 
relevant articles. Other papers of interest found in manual 
search published January 2015 to February 2016 were also 
included. In total, 208 papers were assessed in full text by at 
least one of the authors, depending on their experience and 
fields of expertise, and all papers were discussed by at least 
two. Extraction of data was checked and harmonized by 
two authors (J.T.I. and K.K). Of the 208 papers, 82 were 
excluded using the criteria listed below. Of the 126 remain-
ing papers, 98 contained original data, 26 were classified as 
reviews, one a letter to the editor and one an annotation.
The specific number of included and excluded papers at 
each step is provided in a PRISMA flow chart (Figure 1).
All the 126 studies, both the individual studies and 
reviews, are referred to in the text. Sources of bias in the 98 
individual studies were considered to be mainly related to 
study design, the selection of participants, the size of the 
study, and the methods used to define ADHD and the 
comorbid disorders. All these characteristics were therefore 
assessed and are tabulated in a supplementary table 
(Supplementary 2). Reviews are omitted from this table 
(Supplementary 4 for list). Some additional studies not ful-
filling the inclusion criteria have been mentioned as part of 
the discussion.
Study Selection Criteria
Inclusion criteria. Studies focusing on the comorbidity 
between somatic disease and ADHD in adults (i.e. 18 years 
or older) were included. ADHD was defined according to 
ICD or DSM criteria (ICD-9/ICD-10/DSM-III/DSM-IV/
DSM-5). As indicated in a supplementary table (Supple-
mentary 2), different protocols have been used to classify 
individuals as having aADHD, that is, either (a) aADHD 
clinically diagnosed, included the use of semi-structured 
interviews; (b) ADHD medication used as a proxy for 
ADHD diagnosis; (c) symptoms of ADHD measured by a 
validated ADHD Symptom Rating scale; (d) information on 
ADHD cases from clinical databases. The properties and 
utility of some aADHD instruments have been reviewed 
(Haavik, Halmoy, Lundervold, & Fasmer, 2010) and are 
summarized in Supplementary 3.
For all studies, the reported diagnoses of somatic dis-
ease/comorbidity were fit into broad disease categories as 
defined in the ICD-10. In the cited studies, these diagnoses 
were obtained either after clinical evaluation or from self-
reports. Due to the large number of somatic comorbidities 
studied and the different protocols involved, it was not fea-
sible to systematically describe the inclusion criteria for 
each of the individual somatic comorbidities, but an over-
view of how the somatic diseases are defined, is summa-
rized in Supplementary 2.
Instruments used for ADHD assessment and the most 
commonly used methods to assess for comorbid disorders 
described in the included studies are briefly described and 
listed in Supplementary 3.
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Exclusion criteria. The following exclusion criteria were 
applied: (a) studies not including ADHD as described under 
inclusion criteria, (b) studies including only children and ado-
lescents, (c) publications not subject to peer review, (d) non-
English papers, (e) single case studies, (f) studies describing 
only psychiatric comorbidities as classified in ICD-10 Chapter 
V: Mental and behavioral disorders, and (g) pharmacological 
trials, for example, focusing on specific treatment options and 
not on the comorbid disorder itself. We also excluded studies 
on traumatic incidents, as we consider these to be outside our 
main focus which is somatic diseases comorbid with aADHD.
Classification of Studies
Based on available evidence, the 98 individual studies were 
classified into three categories (Table 1). Category 1 includes 
conditions where the association between ADHD and somatic 
disease is well established and described in meta-analysis or 
systematic reviews. Category 2 includes conditions where 
there is tentative evidence for an association, the associations 
being described in cohort or case-control studies with clini-
cally diagnosed ADHD and the somatic diseases not only 
being based on self-report questionnaires. Comorbidities 
shown in large population-based studies with diagnoses 
retrieved from clinical databases were also included in this 
category. Category 3 includes conditions where the evidence 
was considered too weak to make conclusions, including 
associations described only in studies where ADHD and/or 
somatic comorbidities are not clinically diagnosed (i.e., 
based on self-report questionnaires only) or where the evi-
dence is limited. This category also includes conditions 
where the combined results clearly showed conflicting 
results. Studies on conditions lacking information on diag-
nostic protocols or the age distribution of the ADHD partici-
pants were also categorized in Category 3.
The somatic diseases included in the present review have 
been broadly grouped using ICD-10 codes, although this 
classification in some instances may be arbitrary (e.g. clas-
sifications of sleep problems), due to the application of 
various diagnostic criteria.
Measurements
ADHD scales. The Adult ADHD Self-Report Scale (ASRS) 
was developed in conjunction with the World Health Orga-
nization and is designed to measure current ADHD 
Figure 1.  Flow diagram (from PRISME).
Source. Moher, Liberati, Tetzlaff, and Altman (2009).
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symptoms. A high symptom score on ASRS is not sufficient 
to clinically diagnose ADHD in adults but is frequently used 
in research literature to define study populations with possi-
ble ADHD (Kessler et al., 2005). The Wender Utah Rating 
Table 1. Name of Disease Category, ICD-10 Code, and Number of Individual Studies Investigating the Association Between Adult 




Association and quality of 
evidencea
In general 4  
 Resistance to thyroid hormone E07.8 1 Association (3)
 Hypothyroidism E00-E03 1 Association (3)
 Diabetes E10-E14 3 No/negative association (3)
Nutritional diseases
 Obesity E66 22 Association (1)
Metabolic disorders E70-E90  
 In general 1 Association (3)
 Albinism E70.3 1 Association (3)
 Maple syrup urine disease E71.0 1 Association (3)
Diseases of the nervous system
 Restless legs G25 6 Association (3)
 Dementia with Lewy bodies G31.83 1 Association (3)
 Epilepsy G40 3 Association (3)
 Migraine G43 2 Association (2)
 Sleep disorders G47 25 Association (1)
 Myotonic dystrophy G71.1 2 Association (3)
 Chronic fatigue syndrome G93.3 2 Association (3)
Diseases of the circulatory system Chapter IX 4 No association (2)
Allergic diseases
 In general 2 Association (3)
 Allergic rhinitis J30 1 Association (3)
Respiratory disorders Chapter X  
 In general 2 Association (3)
 Asthma J46 7 Association (1)
Diseases of the digestive system Chapter K  
 In general 1 Association (3)
 Irritable bowel syndrome K58 2 Association?b (3)
 Celiac disease K90.9 3 Association (2)
Skin disorders Chapter XII  
 In general 1 No association (3)
 Atopic dermatitis L20 1 Association (3)
 Alopecia areata L63 1 No association (3)
 Acne (ICD-10: L70) L70 1 Association (3)
Musculoskeletal disorders Chapter XIII  
 In general 3 Association (3)
 Rheumatoid arthritis M05-M06 1 No association (3)
 Systemic lupus erythematosus M32 2 Association (3)
 Fibromyalgia M79.7 2 Association (3)
 Calvé-Legg-Perthes M91.1 1 Association (3)
Congenital syndromes and anomalies Chapter XVII 12  
Symptoms/signs involving the urinary system R30-R39  
 In general 1 No association (3)
 Enuresis R32 3 Association?b (3)
Note. ICD-10 = International Classification of Diseases; Conditions classified in (1) or ( 2) in bold.
aThe reported studies were classified into conditions (1) where the association between ADHD and the somatic disease is well established, (2) where 
there is tentative evidence for an association, and (3) where evidence is still too weak to make conclusions.
bConflicting evidence. One study shows no association, another study/studies show association. See text for more information.
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Scale (WURS) retrospectively assesses symptoms of ADHD 
in childhood (Ward, Wender, & Reimherr, 1993). For addi-
tional measurements, see Supplement 3.
Measure of obesity. Body mass index (BMI) is defined as 
weight in kilograms divided by height in meters squared. In 
adults, <18.5 kg/m2 is defined as underweight, 18.5 to <25 
kg/m2 is defined as normal, 25.0 to <30 kg/m2 is defined as 
overweight, and a BMI of ≥30 kg/m2 is defined as obese 
(WHO, 1995). BMI is as simple and easy way to evaluate 
obesity and is useful to evaluate obesity trends in the gen-
eral population. However, BMI does not provide an accu-
rate measurement of body fat, nor does it take sex, age, and 
ethnicity into account (Bhurosy & Jeewon, 2013). For addi-
tional measurements, see Supplement 3.
Sleep measurements. Polysomnography is used to record 
several physiologic parameters relevant to sleep, such as 
electroencephalography (EEG), electrooculography 
(EOG), electrocardiography (ECG), chin- and anterio tibi-
alis electromyography (EMG), respiratory effort, airflow, 
and oximetry (Chesson et al., 1997). Polysomnography is 
used in assessing a number of different sleep-related dis-
orders, such as restless legs syndrome periodic limb move-
ments during sleep, central hypersomnias, circadian 
rhythm sleep disorder, and sleep-disordered breathing 
(Kushida et al., 2005). For additional measurements, see 
Supplement 3.
Results
Literature Search and Selection of Papers
A range of different medical conditions have been studied 
in connection with ADHD in adults, as shown in Table 1. 
Most studies represent small clinical samples of ADHD 
patients assessed for a limited number of comorbid condi-
tions, or clinical studies of somatic diseases where comor-
bid aADHD or ADHD symptoms also were diagnosed. A 
limited number of population-based cohort studies have 
also been published during this 20-year period.
The diagnostic protocols and quality of the clinical 
assessments of ADHD varied between studies, as was the 
case for the somatic/medical comorbid conditions. However, 
for the purpose of this literature study, we did not consider 
it appropriate to limit this overview to a specific diagnostic 
protocol or classification system. Thus, the cited preva-
lences are not directly comparable.
ADHD comorbidity with sleep disorders or obesity has 
previously been reviewed. However, for the majority of 
conditions mentioned, the differences in research designs, 
the limited number of cases, and the fact that most condi-
tions were only described in few studies made it unfeasible 
to perform meaningful meta-analyses of prevalences.
Somatic Health in General
ADHD is associated with generally impaired somatic 
health (Nigg, 2013) and increased medical costs (Secnik, 
Swensen, & Lage, 2005) when compared with unaffected 
sex- and age-matched controls, even when no differences 
in health habits were identified (Spencer, Faraone, Tarko, 
McDermott, & Biederman, 2014). In a prospective U.S. 
study including 72 ADHD cases and 479 controls, ADHD 
was diagnosed through clinical interviews in adolescence. 
When reassessed at >10 years, having ADHD was signifi-
cantly associated with impaired general physical health 
(Brook, Brook, Zhang, Seltzer, & Finch, 2013). When ret-
rospectively investigating U.S. health care claims for 2006, 
matching adults with ADHD (n = 31,752) to non-ADHD 
(n = 95,256), adults with ADHD had more physical comor-
bidities and were more likely to use non-psychiatric health 
care compared with controls (Hodgkins, Montejano, 
Sasane, & Huse, 2011).
Obesity (ICD-10: E66)
Clinical samples. Obesity is one of the most frequently 
reported comorbid medical conditions in aADHD. The 
prevalences of clinically diagnosed ADHD and suspected 
ADHD based on rating scales have been reported to be 10% 
to 32% in studies exploring adults with obesity or obesity 
treatment, mainly including female participants (Alfonsson, 
Parling, & Ghaderi, 2012; Altfas, 2002; Docet, Larranaga, 
Fernandez Sastre, & García-Mayor, 2010; Fleming, Levy, 
& Levitan, 2005; Levy, Fleming, & Klar, 2009; Pagoto 
et al., 2010; Vogel et al., 2015). Similarly, in a Dutch study 
with 202 clinically assessed aADHD patients and 189 con-
trols, 16.8% of the ADHD patients had BMI 30 to 39, com-
pared with only 3.7% of the controls (p < .001; Bijlenga, 
van der Heijden, et al., 2013). In contrast, a small U.S. study 
(137 ADHD participants, 124 controls) found no significant 
differences between participants in age-corrected BMI 
(Biederman, Spencer, Monuteaux, & Faraone, 2010).
It is unclear whether the association between ADHD and 
obesity is dependent on ADHD subtypes (Davis et al., 
2009), but there are indications of higher proportions of 
inattentive symptoms/subtypes (Altfas, 2002; Fleming 
et al., 2005).
Non-clinical samples. The above studies were conducted in 
clinical settings. When examining population-based, non-
clinical samples, results have been less consistent. In a pop-
ulation-based U.S. study, Pagoto et al. assessed 6,735 
participants between 18 and 44 years (52% females; Pagoto 
et al., 2009). A diagnosis of aADHD was associated with 
increased risk of overweight and obesity, also when adjust-
ing for demographic characteristics and major depressive 
disorder, but not when controlling for binge eating disorder 
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in the past year. In a French study using ASRS to assess 
aADHD symptoms, the prevalence of being overweight and 
obese was approximately doubled for persons reporting 
ADHD symptoms (Caci, Morin, & Tran, 2014). In a Ger-
man cross-sectional study including 1,622 residents 
between 18 and 64 years, the prevalence of ADHD based on 
self-reported symptoms in obese participants was 9.7% (de 
Zwaan et al., 2011). Similar to findings of Altfas and Pagoto 
et al. (Pagoto et al., 2009), the prevalence increased with the 
degree of obesity. The associations between estimated 
ADHD and obesity were significant when adjusting for 
sociodemographic characteristics, symptoms of anxiety and 
depression and also purging behaviors, indicating that the 
relationship between obesity and ADHD in adulthood is not 
fully explained by binge eating. A small non-clinical Cana-
dian study also found associations between ADHD symp-
toms and overweight/obesity, independent of binge eating 
(Davis, Levitan, Smith, Tweed, & Curtis, 2006).
A population-based U.S. study included 34,653 partici-
pants who were asked about ADHD symptoms (Cortese, 
Faraone, Bernardi, Wang, & Blanco, 2013). In this study, 
remittent ADHD was not significantly associated with obe-
sity, whereas there was an association in adults with persis-
tent ADHD. However, after adjusting for mood and anxiety 
disorders, the association was no longer significant. In con-
trast, a 33-year follow-up study including 111 males, remit-
tent, but not persistent ADHD was associated with obesity, 
also after adjusting for sociodemographic characteristics 
and lifetime mental disorders (Cortese, Ramos-Olazagasti, 
et al., 2013).
The prevalence and comorbidity of ADHD in older 
adults have generally been little explored. In a Dutch study 
including 231 random older participants from the popula-
tion registries (Meanage = 71.6 years), 23 of the participants 
were clinically diagnosed with ADHD (Semeijn et al., 
2013). In this age group, there was no association between 
ADHD and BMI or waist circumference.
Meta-analyses. In a meta-analysis by Cortese et al., on the 
association between aADHD and obesity, 11 data sets with 
a total of 2,046 aADHD participants and 63,747 controls 
were analyzed, including previously unpublished studies 
(Cortese et al., 2015). Studies of individuals in bariatric 
clinics were excluded. The pooled prevalence of obesity 
was 28.2% (95% confidence interval [CI] = [22.8%, 
34.4%]) in adults with ADHD relative to 16.4% [13.4%, 
19.9%] in those without ADHD. When analyzing all age 
groups, age did not influence the association between 
ADHD and obesity, indicating that the relationship may be 
present from childhood (Cortese et al., 2016). This was sup-
ported by two prospective cohort studies from the United 
States (Anderson, Cohen, Naumova, & Must, 2006; Cor-
tese, Ramos-Olazagasti, et al., 2013). The association 
between ADHD and obesity found in the meta-analysis by 
Cortese et al. remained significant when limiting to studies 
where ADHD was diagnosed by direct interview, using 
directly measured height and weight and after adjusting for 
confounding factors.
In a meta-analysis conducted by Nigg et al., a total of 43 
population-based samples or case-control studies including 
703,937 participants in all age groups were included (Nigg 
et al., 2016). The pooled effect size expressed as odds ratio 
(OR) was 1.22 [1.11, 1.34], increasing to 1.37 [1.19, 1.58] 
when limiting data to adults of 18 years or more, and was 
not significant for children.
Combined ADHD and obesity comorbid with other 
conditions. The combination of obesity and ADHD also 
shows comorbidity with other psychiatric disorders, for 
instance mood and anxiety disorders (Cortese, Faraone, 
et al., 2013), and disturbed eating behavior/binge eating 
(Alfonsson et al., 2012; Davis et al., 2006; Nazar et al., 2014; 
Strimas et al., 2008). Compared with obese adults without 
ADHD, obese people with ADHD symptoms are three times 
more likely to suffer from abnormal eating behaviors (Docet, 
Larranaga, Perez Mendez, & Garcia-Mayor, 2012). Obesity 
is also associated with excessive sleepiness, which may pro-
duce ADHD symptoms (Cortese, Konofal, & Lecendreux, 
2008). A mediation analysis conducted as part of a clinical 
study, including 114 patients with obesity, 202 aADHD 
patients, and 154 controls, showed that both sleep duration 
and unstable eating patterns mediated the association 
between BMI and ADHD symptoms. A link between ADHD, 
obesity, and iron deficiency has also been discussed (Cortese 
& Angriman, 2014).
Implications for treatment. Several of the cited studies have 
emphasized the importance of recognizing comorbid condi-
tions for planning optimal treatment of either ADHD or 
obesity. Treatment for obesity in people with ADHD may 
be less successful compared with obese people without 
ADHD (Altfas, 2002; Pagoto et al., 2010), and treatment of 
comorbid ADHD in obese individuals may improve the 
treatment for obesity (Cortese & Castellanos, 2014). Clini-
cians should also consider abnormal eating behaviors as 
contributing to obesity in ADHD patients (Cortese & Mor-
cillo-Peñalver, 2010; Nazar et al., 2014).
Treating ADHD successfully might help people with 
obesity and ADHD to better manage overeating ( Davis, 
2009), reduce self-blame, and facilitate the process of 
regaining control for persons with abnormal eating behav-
iors (Cortese, Bernardina, & Mouren, 2007). Behavioral 
treatment may contribute to weight reduction, but this has 
not yet been investigated in well-controlled studies (Cortese 
& Morcillo-Peñalver, 2010). ADHD medication may act on 
brain pathways involving both ADHD and mediating abnor-
mal eating behaviors (Cortese, Angriman, et al., 2008). It 
has been hypothesized that stimulant treatment may 
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decrease impulsiveness and thus improve abnormal eating 
behaviors (Cortese & Morcillo-Peñalver, 2010). Treatment 
of comorbid ADHD in obese individuals may improve the 
otherwise poor effects of standard treatment strategies for 
obesity (Cortese & Angriman, 2014). This is supported by a 
small Canadian study where ADHD patients treated with 
stimulant medication had a significant weight reduction, 
whereas the weight increased in the non-medicated group 
(Levy et al., 2009). Furthermore, a meta-analysis by Cortese 
et al. limited to studies on unmedicated patients only 
showed a pooled estimate for obesity of OR = 1.43 [1.23, 
1.67], compared with OR = 1.00 [0.87, 1.15] when limiting 
to medicated patients only (Cortese et al., 2016).
Finally, clinicians should be aware that comorbid anxi-
ety and mood disorders may be more directly linked to obe-
sity than to ADHD itself, and also take these disorders into 
account when planning treatment (Cortese, Faraone, et al., 
2013).
Restless Legs Syndrome (RLS; ICD-10: G25)
RLS is a neurological disorder which makes it difficult to 
fall asleep. RLS has a reported population prevalence of 
3% to 34%, generally increasing by age and highest in 
women (Allen et al., 2005; Milligan & Chesson, 2002; 
Rijsman, Neven, Graffelman, Kemp, & de Weerd, 2004). It 
is characterized by an unpleasant feeling in the feet or other 
limbs, combined with an urge to move the limb to relieve 
the discomfort. The symptoms primarily occur when a per-
son is relaxed or trying to sleep, and is often combined with 
paresthesias or dysesthesias. Poor quality of sleep associ-
ated with RLS can lead to hyperactivity and lack of con-
centration, and dopaminergic agents are used to treat the 
condition.
Two small studies showed that the prevalence of RLS is 
higher in persons with ADHD compared with controls 
(Schredl, Alm, & Sobanski, 2007; Zak, Fisher, Couvadelli, 
Moss, & Walters, 2009), and another small study showed 
that ADHD is also more common among patients with RLS 
compared with controls (Wagner, Walters, & Fisher, 2004). 
People with combined ADHD and RLS had more severe 
ADHD symptoms compared with those with ADHD with-
out restless legs symptoms (Zak et al., 2009). In a German 
population- based sample (Roy et al., 2015), crude analysis 
showed that aADHD was associated with RLS. However, 
this association was no longer significant when adjusting 
for sleep disturbances. Pearson et al. reported a non-signifi-
cant increase in the use ADHD medication (amphetamines) 
in 110 restless legs patients (Mage 61 years; p = .09) com-
pared with 54 age- and race-matched controls (Pearson 
et al., 2008). Steinlechner (Steinlechner et al., 2011) found 
that parents of children with ADHD had an increased risk of 
RLS compared with the population prevalence. There is 
also evidence of increased psychiatric comorbidity and 
RLS in families with ADHD (Steinlechner et al., 2011), and 
that symptoms of restless legs are related to depressive 
symptoms among ADHD patients (Schredl et al., 2007). 
Appropriate management of RLS can in some cases cause 
improvement of the comorbid disorder (Becker & Novak, 
2014).
Epilepsy (ICD-10: G 40)
Epilepsy is a common neurological brain disorder defined 
as “an enduring predisposition to generate epileptic sei-
zures” and “the neurobiologic, cognitive, psychological, 
and social consequences of this condition” (Fisher et al., 
p. 471, 2005).
The cognitive dysfunction and behavioral disturbances 
associated with epilepsy have similarities with both the core 
symptoms and adjunctive features of ADHD. The cognitive 
deficits may be a consequence of recurrent seizure activity 
in the brain, adverse effects of anti-epileptic drugs, or it 
could represent an inherent part of the syndrome.
The prevalence of epilepsy in the general population is 
estimated to be around 0.4% to 1% (Forsgren, Beghi, Oun, 
& Sillanpaa, 2005; Russ, Larson, & Halfon, 2012), with 
decreasing prevalence and incidence with age. Thus, like 
for ADHD, the majority of cases with childhood-onset epi-
lepsy will remit over time, although accompanying symp-
toms, comorbidity, and impairment may remain (Sillanpaa 
et al., 2015).
A reciprocal comorbidity between ADHD and epilepsy 
is well known in pediatric populations (Davis et al., 2010; 
Socanski, Aurlien, Herigstad, Thomsen, & Larsen, 2013); 
however, less is known about the comorbidity between the 
two disorders in adults. We found only two studies investi-
gating the prevalence and co-occurrence of ADHD in adult 
patients with epilepsy (from both the same group and sur-
vey [Ettinger et al., 2015; Ottman et al., 2011]) and no pub-
lished study investigating the prevalence of epilepsy in 
adult patients with ADHD. In their population-based, longi-
tudinal health survey including more than 172,000 adults 
aged 18 years or more, Ottman et al. (2011) found a preva-
lence ratio of ADHD of 2.4 (2.0-2.8) among adults with epi-
lepsy relative to a control group without epilepsy. Both the 
diagnoses of epilepsy and ADHD were based on self-
reported lifetime occurrence of the disorders. In a follow-up 
of these data, Ettinger et al. (2015) investigated the pres-
ence and impact of ADHD symptoms in adults with self-
reported epilepsy (Ettinger et al., 2015). Using ASRS, they 
found that 18.4% of adults with epilepsy screened positive 
for ADHD. A positive screen for ADHD was associated 
with greater severity of epilepsy (frequency of seizures, 
more use of anti-epileptic drugs), more comorbidity with 
anxiety and depression, lower quality of life, and worse 
functioning/more disabilities in work and social life. A 
Dutch study found that 2.4% of patients with epilepsy 
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admitted to a special clinic for epilepsy were diagnosed 
with ADHD (van der Feltz-Cornelis & Aldenkamp, 2006), 
compared with a 1% prevalence of ADHD in the Dutch 
population (Kooij et al., 2005).
The comorbidity between ADHD and epilepsy may have 
diagnostic, prognostic, and treatment implications for both 
disorders. Central stimulants may theoretically increase sei-
zure susceptibility, although the documentation for this in 
patients with epilepsy is limited and shows conflicting 
results (Brown, Becker, Pollard, & Anderson, 2013; 
Gonzalez-Heydrich et al., 2010). We found only two small 
studies of methylphenidate (MPH) treatment in adults with 
epilepsy (Moore, McAuley, Long, & Bornstein, 2002; van 
der Feltz-Cornelis & Aldenkamp, 2006); none of these 
demonstrated adverse effects of this treatment.
Migraine (ICD-10: G43)
Migraine is an episodic headache disorder, with attacks of 
pain and time-limited neurological dysfunction. Migraine is 
common in the general population and usually starts in ado-
lescence or early adulthood. The prevalence is approxi-
mately 10% to 15%, and females are more often affected 
than males (Fasmer, Halmoy, Oedegaard, & Haavik, 2011). 
Thus, compared with ADHD, migraine has a very different 
profile regarding its prevalence, gender distribution, and age 
of onset. Both migraine and ADHD have a strong genetic 
basis, and a similar well-established comorbid connection 
with both mood and anxiety disorders is found in clinical 
and epidemiological studies (Fasmer et al., 2012). Cognitive 
dysfunction is not usually thought to be associated with 
migraine, apart from changes occurring during acute attacks.
Two large Norwegian studies showed an association 
between ADHD and migraine. Using data from the 
Norwegian Prescription Database, a positive and significant 
association between prescription of anti-migraine and 
ADHD medication was found for all age groups between 20 
and 50 years and for both genders, with ORs ranging from 
1.8 to 2.8 (Fasmer et al., 2012).
In a cross-sectional study of aADHD patients (n = 572) 
and community controls (n = 675), the prevalence of 
migraine was higher in the patient group compared with the 
controls (28.3% vs. 19.2%, p = .001) (Fasmer, Halmoy, 
Oedegaard, & Haavik, 2011). The difference from controls 
was more marked for men (22.5% vs. 10.7%, OR = 2.43, CI 
= [1.51, 3.90]) than for women (34.4% vs. 24.9%, OR = 
1.58, CI = [1.13, 2.21], although not significanlty so. 
Among the controls, the presence of migraine was associ-
ated with higher scores on both ASRS and WURS.
Sleep Disorders (ICD-10: G47)
ADHD and ADHD symptoms in adults are related to a 
variety of sleep problems and sleep-related disturbances, 
both in clinical and non-clinical samples (Boonstra et al., 
2007; Fargason, Hollar, White, & Gamble, 2013; Gau 
et al., 2007; Kass, Wallace, & Vodanovich, 2003; Oosterloo, 
Lammers, Overeem, de Noord, & Kooij, 2006; Schredl 
et al., 2007; Surman et al., 2009; Vogel et al., 2015; Walters, 
Silvestri, Zucconi, Chandrashekariah, & Konofal, 2008; 
Yoon, Jain, & Shapiro, 2012). Fisher et al. (2014) found 
that 80% of adults with ADHD reported sleep problems, 
regardless of sex and ADHD subtype. Sleep problems were 
more common in aADHD than in controls, also when tak-
ing psychiatric comorbidity and psychotropic medication 
into account (Schredl et al., 2007; Surman et al., 2009). 
Furthermore, persons with sleep problems performed 
worse on neuropsychological testing for attention (Fisher 
et al., 2014). Subjectively, patients with ADHD (without 
current psychiatric comorbidity or ADHD pharmacother-
apy) reported worse sleep quality than controls (Philipsen 
et al., 2005), with more insomnia and problems with the 
sleep–wake pattern (Schredl et al., 2007). In a clinical sam-
ple of ADHD patients without psychiatric comorbidity and 
denying having insomnia symptoms, the ADHD sample 
reported more sleep quality problems compared with con-
trols (Fargason et al., 2013). Measured objectively by poly-
somnography, adults with ADHD showed increased 
nocturnal activity compared with controls (Kooij, 
Middelkoop, van Gils, & Buitelaar, 2001; Middelkoop, 
Van Gils, & Kooij, 1997; Philipsen et al., 2005; Sobanski, 
Schredl, Kettler, & Alm, 2008), although one study found 
no difference between the groups (Boonstra et al., 2007). 
Several studies show that people with ADHD have longer 
sleep latency than controls (Boonstra et al., 2007; Sobanski 
et al., 2008), but the results are conflicting (three studies 
showing no difference between ADHD patients and con-
trols: Kooij et al., 2001; Middelkoop et al., 1997; Philipsen 
et al., 2005).
Excessive daytime sleepiness affects 37% of adults with 
ADHD (Oosterloo et al., 2006), and appears to be a predic-
tor of academic and overall functional impairment among 
students with ADHD (Langberg, Dvorsky, Becker, & 
Molitor, 2014). Furthermore, sleepiness and inattention can 
correlate in ADHD patients (Oosterloo et al., 2006). 
However, a small study by Sangal and Sangal (2004) 
showed no correlation between self-reported sleepiness and 
current inattentive symptoms, concluding that sleepiness is 
not a major contributor to inattention in aADHD individu-
als. It is important to be aware of the possible diagnostic 
confusion between aADHD and hypersomnia or narcolepsy 
using self-report questionnaires, as there is a high degree of 
symptom overlap (Oosterloo et al., 2006).
Sleep and ADHD subtype. Studies investigating the associ-
ation between ADHD and comorbid sleep disorders with 
respect to ADHD subtypes show diverging results. Both 
inattentive and hyperactive-impulsive ADHD symptoms 
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have been associated with delayed sleep timing (Gamble, 
May, Besing, Tankersly, & Fargason, 2013). In a study of 
62 students diagnosed with ADHD, students with the inat-
tentive subtype did not differ from those with combined 
subtype on self-ratings of daytime sleepiness (Langberg 
et al., 2014). However, in two studies with a total of 62 
non-medicated patients with ADHD, sleep problems were 
associated with having the combined ADHD subtype and 
symptoms of hyperactivity/impulsivity (Mahajan, Hong, 
Wigal, & Gehricke, 2010; Van Veen, Kooij, Boonstra, 
Gordijn, & Van Someren, 2010), and hyperactivity alone 
has been associated with decreased sleep duration (Gau 
et al., 2007). No significant associations were found 
between inattention and sleep quality, suggesting that 
sleep problems are connected with hyperactive-impulsive 
but not inattentive symptoms (Mahajan et al., 2010). In 
contrast to these results, which were based on small sam-
ples, other studies found that symptoms of inattention 
were most evidently associated with disturbed sleep, 
delayed circadian rhythm, and greater sleep need (Bae 
et al., 2010; Caci, Bouchez, & Bayle, 2009; Gau et al., 
2007; Rybak, McNeely, Mackenzie, Jain, & Levitan, 
2007; Voinescu, Szentagotai, & David, 2012).
Symptom severity. The severity of sleep problems is posi-
tively correlated with the number of ADHD symptoms, 
both among ADHD patients and in the general population 
(Gau et al., 2007; Mahajan et al., 2010; Schredl et al., 2007), 
also when taking ADHD comorbidity and medication into 
account (Schredl et al., 2007). The severity of daytime 
ADHD symptoms was also associated with the level of 
sleep problems (Schredl et al., 2007). Daytime sleepiness is 
associated with increased ADHD severity (Gamble et al., 
2013), and is a predictor of academic and overall functional 
impairment among students with ADHD (Langberg et al., 
2014).
Insomnia (ICD-10: G47.0). Insomnia implies dissatisfaction 
with sleep quantity or quality due to difficulty initiating 
sleep, maintaining sleep or early-morning awakenings. The 
symptoms impair daily functioning and affect about 6% to 
12% of the adult population when ascertained according to 
formal diagnostic systems (Pallesen, Sivertsen, Nordhus, & 
Bjorvatn, 2014). Insomnia is common in people with 
ADHD; one study showed that 78% of the 40 non-medi-
cated ADHD participants included suffered from sleep-
onset insomnia (Van Veen et al., 2010), another study 
showed that the higher reports of insomnia among ADHD 
patients compared with controls may be related to the pres-
ence of depressive symptoms (Schredl et al., 2007). Sleep-
onset insomnia, defined as difficulty getting to sleep at the 
desired bedtime, is the most problematic sleep problem 
reported in ADHD (Fisher et al., 2014), and is also a promi-
nent initial side effect of stimulant medication.
Circadian rhythm sleep disorder, delayed sleep phase type (ICD-
10: G47.21). Delayed sleep phase syndrome implies a dis-
turbance in the normal circadian rhythm. It is characterized 
by a preference for late sleep and late rising, with sleep-
onset insomnia when trying to get to sleep early and high 
activity in the late evening/night. The prevalence in the 
adult general population is estimated at 0.13% to 3.1% 
(Ando, Kripke, & Ancoli-Israel, 2002; Schrader, Bovim, & 
Sand, 1993). In a Dutch study by Bijlenga et al., including 
202 adults with clinically diagnosed ADHD (18-65 years) 
and 189 controls, delayed sleep phase syndrome was more 
prevalent among aADHD patients (26%) than among con-
trols (2%; Bijlenga, van der Heijden, et al., 2013). Adults 
with comorbid ADHD and insomnia were found to have 
significant circadian rhythm delay, the severity of ADHD 
symptoms and neuropsychological deficits correlating with 
the delay (Gamble et al., 2013; Rybak et al., 2007). In con-
trast to the controls, the patients with aADHD had the same 
prevalence of delayed sleep phase syndrome independent of 
age, the authors suggesting that delayed sleep phase syn-
drome in ADHD is not age related (Bijlenga, Van Someren, 
et al., 2013).
Hypersomnia (ICD-10: G47.1 and G47.4). Central hypersom-
nias such as idiopathic hypersomnia (G47.1) and narco-
lepsy (G47.4) cause excessive daytime sleepiness not 
caused by disturbances in nocturnal sleep or circadian 
rhythm. In a study including 74 patients with narcolepsy 
(G47.4) or idiopathic hypersomnia (G47.1), 19% of the 
affected patients fulfilled the criteria for aADHD when 
using self-report measures (Oosterloo et al., 2006). The 
overlap between symptoms of hypersomnia and ADHD 
might lead to misdiagnosis of both diagnoses (Oosterloo 
et al., 2006). However, both ADHD and hypersomnias are 
treated using psychostimulant medication, indicating a rela-
tion between these disorders (Oosterloo et al., 2006).
Sleep-disordered breathing (ICD-10: G47.3 and G47.8). Sleep-
disordered breathing includes a spectrum of sleep-related 
abnormalities such as upper airway resistance syndrome 
(G47.8) and obstructive sleep hypopnea syndrome (G47.3), 
with symptoms such as snoring, episodes of breathing cessa-
tion during sleep, and excessive daytime sleepiness. Approx-
imately 13% of men and 6% of women suffer from moderate 
to severe sleep-disordered breathing (Peppard et al., 2013). 
Of 78 severely obese adults with ADHD, 56% had sleep 
apnea (Levy et al., 2009). The cognitive and behavioral 
symptoms of obstructive sleep apnea such as inattention, 
poor planning, and restlessness, are similar to symptoms of 
ADHD (Ball, Wooten, & Crowell, 1999), and treatment may 
have a positive effect on ADHD symptoms (Youssef, Ege, 
Angly, Strauss, & Marx, 2011). In a case report of six adults 
with clinically diagnosed ADHD and impaired sleep quality, 
all had polysomnographic evidence of sleep-disordered 
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breathing (Surman, Thomas, Aleardi, Pagano, & Biederman, 
2006). One study indicated that sleep-disordered breathing 
symptoms are mainly associated with increased BMI and 
smoking, and not ADHD symptomatology as such (Schredl 
et al., 2007). In a Turkish study of 81 treatment-naïve 
obstructive sleep apnea patients and 32 controls, the preva-
lence of ADHD symptoms was similar in patients with 
obstructive sleep apnea and controls (Oguzturk, Ekici, 
Cimen, Ekici, & Senturk, 2013). One study found a correla-
tion between low oxygen saturation and hyperactivity in 
patients with sleep-disordered breathing (Sangal & Sangal, 
2004). In two small case studies with a total of nine aADHD 
patients, it was observed that treatment for sleep apnea 
relieved their ADHD symptoms, and some were rediagnosed 
as having sleep apnea instead of ADHD (Ball et al., 1999; 
Naseem, Chaudhary, & Collop, 2001). According to these 
results, sleep apnea may actually be misdiagnosed as ADHD.
Periodic limb movements during sleep (ICD-10: G47.61). In the 
disorder called periodic limb movements during sleep, con-
tractions of muscles during sleep causes periodic episodes 
of repetitive limb movements. Unmedicated patients with 
ADHD show increased periodic limb movements during 
sleep compared with controls (Philipsen et al., 2005; Soban-
ski et al., 2008).
Impact of stimulant medication. Sleep problems are present in 
unmedicated adults with ADHD, but stimulant treatment is 
also associated with dysregulation of sleep. Common initial 
side effect of stimulant medication is insomnia or delayed 
sleep-onset latency (Kirov & Brand, 2014; Kooij & Bijlenga, 
2013). Atomoxetine may also cause insomnia as an adverse 
effect (Adler, Liebowitz, et al., 2009). It varies between indi-
viduals whether stimulants cause insomnia or not, and sleep 
problems such as sleep-onset latency may decrease with time 
as the medication is finished titrated and ADHD symptoms 
improve (Stein, Weiss, & Hlavaty, 2012). If ADHD medica-
tion affects the circadian rhythm, the effect on sleep may be 
less obvious and appear later (Stein et al., 2012).
Subjectively measured, ADHD participants using methyl-
phenidatereported an improvement in sleep quality (Kooij 
et al., 2001). A study of the central stimulant lisdexamphet-
amine including 420 participants showed no difference in 
global sleep quality among aADHD patients receiving lis-
dexamphetamine compared with placebo, and daytime func-
tioning in the stimulant treatment group improved compared 
with the aADHD group receiving placebo (study not included 
in the literature search, as it is not a study primarily on comor-
bidity; Adler, Goodman, Weisler, Hamdani, & Roth, 2009). A 
clinical study including 80 aADHD patients all denying 
insomnia symptoms (treated with stimulants, n = 39; with 
non-stimulants, n = 15 and with no medication, n = 26), 
showed significantly more sleep disturbance and prolonged 
sleep latency compared with controls (n = 25). This result 
indicated that medical treatment, including stimulant treat-
ment, did not account for the sleep quality problems in the 
aADHD group (Fargason et al., 2013).
Objectively measured, sleep-onset latency increased 
(Boonstra et al., 2007) and sleep duration (Gamble et al., 
2013) was reduced in patients treated with stimulant medica-
tion compared with those without such medication, although 
no change (Kooij et al., 2001) and less sleep latency were 
also reported (Sobanski et al., 2008). Objectively measured, 
sleep quality and efficiency improved (Boonstra et al., 2007; 
Sobanski et al., 2008) in ADHD participants using MPH 
compared with placebo (Boonstra et al., 2007) or compared 
with a premedication baseline (Sobanski et al., 2008). Also 
when adjusted for depression and anxiety symptoms, sleep 
was more consolidated with less interrupted sleep (Boonstra 
et al., 2007). Regarding the impact of MPH treatment on 
nocturnal activity, the results are conflicting: Sobanski et al. 
(2008) found unchanged number of periodic limb move-
ments during sleep in contrast to Kooij et al. (2001) who 
found reduced nocturnal activity. Improvements in sleep 
quality may, however, not be directly related to stimulant 
medication, as the same proportion (one third) of a total of 
831 ADHD participants (n = 831) experienced sleep 
improvement independent of receiving stimulant treatment 
or placebo (Surman & Roth, 2011).
Treatment. ADHD is a 24-hr disease, with symptoms 
appearing both at day- and nighttime (Stein et al., 2012). 
Before starting treatment for ADHD, patients should be 
screened for sleep disorders and sleep patterns, to more eas-
ily track changes in sleep associated with stimulant treat-
ment (Stein et al., 2012). Sleep disorders are associated 
with cognitive impairment, thus ADHD symptomatology 
may improve if comorbid sleep disorders are adequately 
treated in addition to specific treatment for ADHD (Schredl 
et al., 2007). If the patient is using medical treatment for 
ADHD and has sleep problems, give advice on sleep 
hygiene and consider reducing the stimulant treatment in 
the late afternoon, add a small dose of stimulant treatment 
earlier in the evening or switch to non-stimulant medication 
(Brown & McMullen, 2001; Hvolby, 2015; Lecendreux & 
Cortese, 2007). Usually, insomnia as a side effect of stimu-
lant treatment attenuates after 1 to 2 months treatment 
(Lecendreux & Cortese, 2007). When treating aADHD with 
delayed sleep phase syndrome, one can combine stimulant 
treatment with exogenous melatonin together with bright 
light therapy and good sleep hygiene; Kooij et al. describe 
this treatment in detail (Kooij & Bijlenga, 2013).
Other Neurological Disorders  
(ICD-10: Chapter XI)
Dementia with Lewy bodies (ICD-10: G31.83). Symptoms of 
dementia with Lewy bodies include mental decline, 
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Parkinson-like motor symptoms, sleep disturbances, and 
hallucinations. In a study from Argentina including patients 
with Lewy body dementia (n = 109), Alzheimer’s disease (n 
= 251), and sex-, age-, and education-matched controls (n = 
149), previous symptoms of aADHD were associated with 
risk of Lewy body dementia (Golimstok et al., 2011). The 
prevalence of previous ADHD symptoms was significantly 
higher than in both the Alzheimer group (OR = 4.9 [2.8, 
8.4]) and the control group (OR = 5.1 [2.7, 9.6]). ADHD 
symptoms were tested according to DSM-IV criteria using 
WURS and ASRS, and in patients with cognitive impair-
ment information was obtained from an informant knowing 
the patient for at least 10 years. Both ADHD and Lewy 
body dementia are related to a hypodopaminergic state; this 
being a possible explanation for the association (Golimstok 
et al., 2011).
Myotonic dystrophy 1 (DM1; ICD-10: G71.1). Douniol and 
coauthors described the psychiatric phenotype of the juve-
nile form of DM1(Douniol et al., 2009), the most common 
inherited neuromuscular disease, with autosomal dominant 
transmission. The study included 28 people with juvenile 
DM1 from 7 to 24 years of age. In the total sample, includ-
ing both children and adults, 28.6% had ADHD, all inatten-
tive subtypes. ADHD was measured by ASRS in the adults. 
A study by Echenne et al. describes adult cases with comor-
bid ADHD and myotonic dystrophy, but it is not known 
how ADHD was diagnosed or if the participants were tested 
for ADHD as adults (Echenne et al., 2008).
Chronic fatigue syndrome (CFS; ICD-10: G93.3). CFS is char-
acterized by a combination of prolonged and severe fatigue 
with non-specific somatic manifestations and cognitive 
symptoms, including difficulties in concentration, short-
term memory and thinking, impaired attention and slow 
processing speed (Valdizán Usón & Idiazábal Alecha, 
2008). These cognitive symptoms may mimic symptoms of 
ADHD and possibly share some underlying pathophysio-
logical mechanisms (Bellanti et al., 2005). Fatigue symp-
toms are also commonly reported in aADHD and may affect 
neuropsychological functioning (Fisher et al., 2014).
We found only one study on prevalence of aADHD in 
CFS patients (Sáez-Francàs et al., 2012). In their clinical 
sample of 158 adults with CFS, 97% women, Sáez-Francàs 
et al. found that 47 patients (29.7%) fulfilled diagnostic cri-
teria for childhood ADHD assessed retrospectively, and 33 
patients (20.9%) were found to still meet criteria for ADHD 
in adulthood. We found no studies on the prevalence of CFS 
in samples of adults with ADHD, nor any population-based 
studies on CFS and aADHD; thus, the possible relationship 
between these conditions and the magnitude of the problem 
is not clear. Young et al. (2013a) described three female 
cases with CFS (38-58 years), who were also found to fulfill 
criteria for ADHD dating back to childhood (Young, 2013a). 
In all three cases, symptoms of chronic fatigue and/or pain, 
and general and occupational functioning, improved after 
treatment with central stimulants.
Despite the limited amount of literature, the suggested 
association between ADHD and CFS is clinically interest-
ing, as central stimulants, the first-line pharmacological 
treatment of ADHD, have shown positive effects on both the 
core symptom of CSF, that is, chronic fatigue (Blockmans, 
Persoons, Van Houdenhove, & Bobbaers, 2006), and the 
associated cognitive symptoms, such as executive dysfunc-
tion (Young, 2013b).
Endocrine Diseases (ICD-10: E00-E35)
Resistance to thyroid hormone (RTH; ICD-10: E07.8). RTH 
usually involves mutations in the thyroid hormone receptor 
β gene and is often transmitted as an autosomal dominant 
trait. Classical features include ADHD, tachycardia, and 
growth delay. Brucker-Davis et al. (1995) described 104 
RTH patients and 114 unaffected participants, both children 
and adults. ADHD was found to be common among the 
RTH patients; more common in males (72%) than in 
females (43%). Among adults, 42% had ADHD in the RTH 
group compared with 4% in the non-RTH group. Full-scale 
IQ was lower among RTH patients than among controls, 
and 38% of the patients had IQ less than 1 standard devia-
tion (SD) below the mean; however, there was no correla-
tion between IQ and ADHD in the RTH patients.
Hypothyroidism (ICD-10: E00-E03). Hypothyroidism is an 
endocrine disorder in which the thyroid gland does not pro-
duce enough thyroid hormone, leading to a large range of 
symptoms, including weight gain, fatigue, and poor ability 
to tolerate cold. In the previously mentioned study by 
Hodgkins et al., investigating U.S. health care claims for 
2006 (aADHD: 31,752; non-ADHD: 95,256), hypothyroid-
ism was significantly more common in adults with ADHD 
compared with those without (p ≤ .0001; Hodgkins et al., 
2011).
Diabetes (ICD-10: E10-E14). Pancreas insulin cells diabetes 
mellitus is a heterogeneous group of metabolic diseases 
characterized by high blood glucose levels over prolonged 
periods of time. Interestingly, diabetes (ICD-10: E10-E14) 
was significantly higher in the non-ADHD group compared 
with the ADHD group in the above-mentioned study inves-
tigating U.S. health care claims (p ≤ .0001; Hodgkins et al., 
2011). However, a Dutch study including older adults with 
ADHD (n = 23) and controls (n = 208) found no difference 
in self-reported diabetes between the individuals with 
ADHD and controls (Semeijn et al., 2013). Furthermore, a 
U.S. study including adult patients with ADHD (n = 98) and 
controls (n = 100) showed no significant differences in the 
number of self-reported diabetes (Spencer et al., 2014).
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Metabolic Disorders (ICD-10: E70-E90)
Bijlenga et al. have reported a significantly increased fre-
quency of self-reported metabolic disorders among adults 
with ADHD compared with controls (Bijlenga, van der 
Heijden, et al., 2013). We also identified studies describing 
the co-occurrence of aADHD or ADHD symptoms with 
several different inborn metabolic diseases:
Albinism (ICD-10: E70.3). Albinism is an inherited disorder 
causing an absence or reduction of melanin in the hair, skin, 
and/or eyes. The prevalence of albinism worldwide is esti-
mated to 1/17,000 (0.006%), although it varies considerably 
over different continents (Gronskov, Ek, & Brondum-Nielsen, 
2007). In their study of albinism and comorbid ADHD, Kutz-
bach et al. found that 17 of 75 children (22.7%) and 3 of 44 
adults (6.8%) met criteria for ADHD, and that the majority of 
these had the hyperactive/impulsive subtype (Kutzbach, Sum-
mers, Holleschau, King, & MacDonald, 2007).
Maple syrup urine disease (MSUD; ICD-10: E71.0). MSUD is 
an inborn error of metabolism, with clinical features includ-
ing neuropsychiatric disturbances and neurologic deteriora-
tion. Muelly et al. (2013) studied neuropsychiatric 
symptoms in 37 patients with MSUD aged 5 to 35 years; 26 
treated with diet and 11 with liver transplantation. They 
found the cumulative lifetime incidence of ADHD to be 
54% among MSUD patients on dietary therapy and 82% 
among patients with liver transplants. They concluded that 
neurochemical deficiencies correlated with neuropsychiat-
ric morbidity (Muelly et al., 2013).
Diseases of the Circulatory System  
(ICD-10: Chapter IX)
Possible increased risk of cardiovascular events due to 
stimulant treatment of ADHD is an important clinical issue. 
Long-term (≥12 months) stimulant treatment is associated 
with increased heart rate and increased blood pressure, but 
no evidence has so far indicated elevated risk of serious car-
diovascular events (Hammerness, Karampahtsis, Babalola, 
& Alexander, 2015). Although this is a debated issue, only a 
few studies have investigated the comorbidity of ADHD 
and cardiovascular disorders per se; none of them focusing 
on cardiovascular disease alone.
The study by Bijlenga et al. on sleep patterns (202 
aADHD patients, 189 controls) reported a significantly 
increased frequency of self-reported cardiovascular disease 
among adults with ADHD compared with controls 
(Bijlenga, van der Heijden, et al., 2013). In contrast to this, 
another Dutch study including older (Mage = 71.6) adults 
with ADHD (n = 23) and controls (n = 208) found no differ-
ence in self-reported hypertension and cardiovascular dis-
ease between the ADHD individuals and controls (Semeijn 
et al., 2013). In line with this result, no significant differ-
ences between adults with ADHD and controls were found 
concerning hypertension and other cardiovascular diseases 
in the previously mentioned study investigating U.S. health 
care claims for 2006 (31,752 aADHD matched with 95,256 
non-ADHD individuals; Hodgkins et al., 2011). 
Furthermore, a U.S. study including adult patients with 
ADHD (n = 98) and controls (n = 100) showed no signifi-
cant difference in the number of self-reported heart attacks 
(Spencer et al., 2014).
Atopic Diseases/Allergic Diseases (Primarily  
ICD-10: Chapter X and Chapter XII)
The results from a systematic review including mainly stud-
ies on children concluded that atopic disease in general was 
not associated with ADHD, but that atopic eczema specifi-
cally appears to be independently associated with ADHD 
(Schmitt, Buske-Kirschbaum, & Roessner, 2010). For fur-
ther information on atopic eczema, we refer to the paragraph 
describing skin disorders. Information on the allergic disor-
ders asthma, allergic rhinitis, atopic dermatitis, and allergic 
conjunctivitis was collected in a study using data from the 
Taiwan National Health Insurance Research Database from 
1996 to 2010. Patients with ADHD (n = 5,811; ICD-9-CM 
diagnosis), patients with tic disorder, patients with comorbid 
ADHD and tic disorder (n = 349), and age/gender-matched 
controls were retrieved (Chen et al., 2013). Most of the 
ADHD patients included were adolescents and young adults. 
Compared with the control group, the ADHD group showed 
a significantly increased risk of having allergic comorbidi-
ties after adjusting for age, gender, and comorbid psychiatric 
disorders. The comorbid ADHD and tic disorders group 
showed the highest prevalence of allergic disease. The 
results pointed to an additive effect of ADHD and tic disor-
der on the association with allergic comorbidities.
Allergic Rhinitis (ICD-10: J 30). A German study focused on 
allergic rhinitis, and by collecting information from the 
German National Health Insurance beneficiaries, 111,394 
patients with allergic rhinitis in 2005/2006 were retrieved 
(Schmitt, Stadler, Kuster, & Wustenberg, 2016). In addi-
tion, information on different comorbid disorders was col-
lected, including hyperkinetic disorder (F 90). The results 
showed that ADHD was more prevalent among those with 
allergic rhinitis compared with those without, RR = 1.21 
[1.13, 1.29]; however, specific information on adults with 
ADHD was not given.
Respiratory Disorders ICD-10: Chapter X
Asthma (ICD-10: J 46). Two studies reported an association 
between unspecific lung diseases and aADHD (Bijlenga, 
van der Heijden, et al., 2013; Semeijn et al., 2013), while 
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there are several studies on aADHD and comorbid asthma 
(Chen et al., 2013; Fasmer, Halmoy, Eagan, Oedegaard, & 
Haavik, 2011; Fasmer, Riise, et al., 2011; Hodgkins et al., 
2011; Karlstad, Nafstad, Tverdal, Skurtveit, & Furu, 2012; 
Secnik et al., 2005; Spencer et al., 2014). Asthma is an 
inflammatory disorder of the airways, following a chronic 
course, but with episodic worsening. Common symptoms 
are wheezing and coughing, caused by reversible airflow 
obstruction and bronchospasm (Handoyo & Rosenwasser, 
2009). As is the case with ADHD, the disorder usually starts 
in childhood, and also similar to ADHD, psychiatric disor-
ders, in particular mood and anxiety disorders, are often 
comorbid problems (Goodwin, Jacobi, & Thefeld, 2003). 
Tobacco smoking may be another factor that is common to 
these conditions (Thomson, Chaudhuri, & Livingston, 
2004). ADHD patients have a higher smoking prevalence 
than the general population. It is uncertain if smoking is a 
cause of asthma, but it aggravates symptoms among people 
prone to asthma, and passive smoking in childhood and pre-
natal exposure are associated with an increased risk of 
asthma (Fasmer, Halmoy, Eagan, et al., 2011).
The relationship between aADHD and asthma has been 
investigated both in clinical samples and using registry data. 
In a U.S. database search, adults with ADHD were signifi-
cantly more likely to have a comorbid diagnosis of asthma 
compared to controls (p < .01 (Secnik et al., 2005). Data 
from the Norwegian Prescription Database showed a higher-
than-expected occurrence of ADHD in 20- to 29-year-olds 
treated for asthma compared with the general population 
(Karlstad et al., 2012). Similarly, another study using the 
Norwegian Prescription Database showed that patients pre-
scribed central stimulants were also prescribed anti-asth-
matic drugs more often than the remaining population 
(Fasmer, Riise, et al., 2011). In this study, a weaker relation-
ship between ADHD and asthma was found in the younger 
age groups (<20 years) than in the older age groups (>20 
years), although the associations were significant across all 
ages. In a cross-sectional questionnaire-based study of 594 
aADHD patients compared with 719 persons from the gen-
eral Norwegian population, the prevalence of self-reported 
asthma was significantly higher in the ADHD group than in 
controls (24.4% vs. 11.3%). In addition, controls with 
asthma had higher scores on ratings of ADHD symptoms 
(Fasmer, Halmoy, Eagan, et al., 2011). These studies point to 
a comorbidity of ADHD and asthma, apparently most pro-
nounced for adult patients, although none of these four stud-
ies adjusted for smoking as a possible confounder.
Diseases of the Digestive System  
(ICD-10: Chapter K)
Irritable bowel syndrome (IBS; ICD-10: K58). IBS causes 
abdominal pain and bloating, and can lead to both diarrhea 
and constipation. In the previously mentioned U.S. database 
search by Secnik et al. (2005), 2,252 adults diagnosed with 
ADHD did not differ significantly from the corresponding 
large control group in the prevalence of IBS (Secnik et al., 
2005). However, the study by Hodgkins et al. (2011), based 
on U.S. health care claims for 2006 (aADHD: 31,752; non-
ADHD: 95,256), found that adults with ADHD reported sig-
nificantly more IBS compared with those without (p ≤ .0001; 
Hodgkins et al., 2011).
Celiac disease (CD; ICD-10: K90.9). CD is an autoimmune 
disease where the ingestion of the wheat protein gluten 
leads to damage and subsequent atrophy of the intestinal 
villi, and thus may compromise nutrient absorption. The 
primary symptoms are diarrhea, abdominal pain, or discom-
fort, with weight loss and anemia being common complica-
tions. CD is estimated to affect 1% to 2% of the population, 
with increasing prevalence in later years due to new screen-
ing methods and the detection of asymptomatic patients.
Zelnik, Pacht, Obeid, and Lerner (2004) studied the 
prevalence of several neurological disorders in a sample of 
111 young patients with CD (Mage = 20 years, 42% men), 
and found that 23 patients (20.7%) had a learning disability 
(LD) and/or ADHD, compared with 10.5% in a control 
group without CD, recruited from the same pediatric gastro-
enterological clinic (Zelnik et al., 2004). Interestingly, the 
gender distribution of LD/ADHD was very even in the CD 
group (20.3% females and 21.2% males), whereas male 
participants were more affected in the control group (12.9% 
vs. 8.7%), as expected in the general population.
Niederhofer & Pittschieler (2006) found an overrepresen-
tation of ADHD symptoms in patients with CD and investi-
gated possible effects of a gluten-free diet on ADHD 
symptoms in a sample of patients with CD consisting of both 
children and adults (n = 78, age = 3-57 years [M = 19.3]; 
(Niederhofer & Pittschieler, 2006). Interestingly, although 
results should be interpreted with caution due to the small 
sample size and open study design, they found a significant 
reduction of ADHD-like symptomatology after at least 6 
months of gluten-free diet. The reduction of ADHD symp-
toms further correlated with pain reduction. The same 
authors also investigated the presence of CD in a primary 
sample of patients with ADHD (n = 67, 52 males, age = 7-42 
years [M = 11.4]), and found that 10 of the 67 patients were 
positive for CD (seven males, 13.5%, and three females, 
20.0%), defined by the presence of CD-specific antibodies 
(antigliadine and antiendomysium) in blood serum. A glu-
ten-free diet of at least 6 months was associated with 
improvement of ADHD symptoms also in this patient sam-
ple (Niederhofer, 2011).
Skin Disorders (ICD-10: Chapter XII)
For unspecific skin disorders, the study by Bijlenga et al. on 
ADHD and sleep patterns showed no differences in 
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self-reported skin disorders between 202 aADHD patients 
and 189 controls (Bijlenga, van der Heijden, et al., 2013).
Atopic dermatitis (ICD-10: L 20). Atopic dermatitis is a 
chronic, pruritic inflammatory skin condition characterized 
by pruritus and red swollen skin. Several studies, mainly on 
children, have shown a positive association between atopic 
dermatitis and ADHD symptoms (Gee & Bigby, 2011). For 
adults, a Turkish study investigating 60 adult patients with 
atopic dermatitis and 50 non-atopic control participants 
found significantly more ADHD symptoms in patients with 
atopic dermatitis than in controls, the association being 
strongest in females (Cicek et al., 2009). A self-report scale 
showed that features of inattention, hyperactivity, and 
impulsivity were all associated with atopic dermatitis, and 
the authors concluded that co-occurrence of ADHD should 
be taken into consideration when treating patients with 
atopic dermatitis.
Alopecia areata (AA; ICD-10: L 63). AA is a likely autoim-
mune disorder causing hair loss. A register-based study 
from Taiwan (n = 5,117 patients with AA and n = 20,468 
controls) investigated psychiatric comorbidity in patients 
with AA and found no association with AA and aADHD 
(Chu et al., 2012).
Acne (ICD-10: L70). Acne is a skin disorder characterized by 
inflammation of the pilo sebaceous follicle. A registry-
based U.S. study including both children and adults showed 
that ADHD was twice as likely to be associated with acne 
relative to all other dermatological disorders (Gupta, Gupta, 
& Vujcic, 2014), also when adjusting for age, sex, atopic 
dermatitis, anxiety, depression, and stimulant medication. 
However, there were few participants >18 years.
Musculoskeletal Disorders  
(ICD-10: Chapter XIII)
Adults with ADHD report chronic musculoskeletal and skel-
etal complaints, including fibromyalgia (FMS), more fre-
quently than controls without ADHD (Bijlenga, van der 
Heijden, et al., 2013; Spencer et al., 2014). Stray and coau-
thors (2013) investigated motor regulation problems and 
reported musculoskeletal pain in 25 adults with ADHD (all 
responders to treatment with MPH) and 23 control individu-
als. The adults with ADHD scored higher on tests indicating 
more motor problems than control individuals. As much as 
80% of the ADHD patients reported widespread pain; pain 
level was more severe and more often widespread than in the 
control individuals. The authors concluded that motor inhi-
bition problems and heightened muscle tone are, as in chil-
dren with ADHD, increased in adults with ADHD, and that 
the more widespread and higher pain levels may represent 
long-term secondary effects of these muscular problems.
Rheumatoid arthritis (ICD-10: M05-M06). In the Dutch study 
including older adults with ADHD (n = 23) and controls 
(n = 208), no difference in self-reported rheumatoid arthritis 
(ICD-10: M05-M06) was found between the ADHD 
patients and controls (Semeijn et al., 2013).
Systemic lupus erythematosus (SLE; ICD-10: M32). SLE (ICD-
10: M32) is an autoimmune connective tissue disorder 
where many internal organs in the body, as well as the ner-
vous system, may be affected. Neuropsychiatric symptoms 
are common, as described in a systematic review by 
Meszaros and coauthors in 2012 (Meszaros, Perl, & Fara-
one, 2012). In a recent Chinese study, Gao and coworkers 
investigated whether SLE patients (n = 117) had more 
ADHD symptoms than healthy age- and sex-matched con-
trols (n = 64; Gao, Lo, & Mok, 2015). ADHD symptoms 
were assessed by the ASRS. Possible ADHD was found in 
7.7% of SLE patients and 6.3% of controls (p = 1.0); how-
ever, SLE patients had more clinically significant items in 
the inattention domain of the ASRS than the controls (p = 
.006), especially if they had previous cerebral involvement 
(p = .004). Anxiety and depressive symptoms correlated 
with ADHD symptoms.
N-acetylcysteine (NAC) has been reported to improve 
psychiatric symptoms in various disorders (Berk et al., 
2008; Bernardo et al., 2009). In a randomized- controlled 
trial, Garcia and coworkers (2013) investigated whether 
ADHD might serve as a marker for neuropsychiatric dis-
ease in SLE patients and as a target for treatment with NAC. 
They included 49 SLE patients and 46 matched healthy 
controls, and randomized 24 of the SLE patients to receive 
placebo or NAC in two dosages. The authors concluded that 
increased scores on the ASRS indicate previously unrecog-
nized and clinically significant ADHD symptoms that 
respond to NAC treatment in SLE patients.
Fibromyalgic syndrome (FMS; ICD-10: M79.7).  Studies focus-
ing on the comorbidity between aADHD and FMS are few, 
small, and still exploratory in nature. In a sample of 201 
women with FMS, 32.3% fulfilled criteria of childhood 
ADHD, compared with 2.5% in an aged-matched control 
group of healthy women (Reyero et al., 2011).
Based on clinical reports of aADHD with co-occurring 
fibromyalgic complaints, who experienced relief of their 
complaints after medication for ADHD, Krause et al. con-
ducted a German pilot study to investigate the comorbidity 
between ADHD and FMS. Twelve patients with FMS were 
compared with 12 patients with pain of other origin. The 
FMS patients had significantly higher symptom scores of 
ADHD (both past and present) than the other pain patients 
(Krause et al., 1998).
In a Dutch study including 44 patients with FMS, 11 (25%) 
of the patients met the criteria for ADHD after being clinically 
interviewed (Derksen, Vreeling, & Tchetverikov, 2015).
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Legg-Calve-Perthes disease (LCPD; ICD-10: M91.1). LCPD is a 
disease which leads to deformation of the femoral head, is 
diagnosed in children, and is associated with early hip dys-
function and osteoarthritis of the hip. Hailer and coauthors 
studied health-related quality of life, physical activity, and 
behavior patterns in 116 adult patients with LCPD, who had 
been treated at Uppsala University Hospital between 1978 
and 1995 (Hailer, Haag, & Nilsson, 2014). The patients 
answered self-report questionnaires by interview using 
ASRS to assess ADHD symptoms. A total of 28% had 
ASRS scores corresponding to a likely ADHD diagnosis, 
and a higher ASRS score was associated with a lower score 
on quality of life questionnaires.
Congenital Syndromes and Anomalies  
(Mainly ICD-10: Chapter XVII)
This is a heterogeneous disease entity where various organ 
systems are affected, either as isolated anomalies with 
largely unknown etiology occurring sporadically or as mul-
tiple anomalies which may or may not be part of known 
syndromes or associations. The anomalies may be associ-
ated with environmental exposures or have well-defined 
genetic causes. In all instances, ADHD symptoms may be 
an important feature of the condition, for some genetic syn-
dromes even the presenting feature. If all the clinical crite-
ria of ADHD are fulfilled, it is recommended to separately 
diagnose this as ADHD, irrespective of its association with 
other well defined and perhaps underlying illnesses (APA, 
2013). Most of the research on syndromes and associated 
neuropsychiatric disorders such as ADHD and autism is 
based on children, while we focus on studies where adults 
are included.
Tuberous sclerosis (ICD-10: Q85.1) is an autosomal 
dominant genetic syndrome associated with neuropsychiat-
ric manifestations such as mental retardation, autism spec-
trum disorders (ASD), and ADHD (de Vries et al., 2005). 
ADHD is assumed to be associated with brain lesions due to 
this disorder (Hunt, 1998). Muzykewicz et al. (2007) 
reported that 30% of 241 children and adults (average 20 
years, range = 8 months - 63.4 years) with tuberous sclero-
sis had ADHD symptoms (Muzykewicz et al., (2007). A 
similar fraction of patients had anxiety or depression.
Chromosomal aberrations may also be associated with 
ADHD, as well as with other psychiatric disorders. The 
22q11.2 deletion syndrome (ICD-10: D82.1; velo-cardio-
facial [VCFS] or DiGeorge syndrome) is among the most 
studied genetic syndromes in psychiatry. Whereas high 
rates of ADHD have been reported in children, psychotic 
disorders may be the most prominent psychiatric disorders 
in adulthood (Murphy, 2005); however, psychiatric morbid-
ity in adults is not yet adequately documented (Baker & 
Vorstman, 2012). The clinical phenotype of this relatively 
common syndrome (1/2,000-1/4,000 live births) is highly 
variable. In their comprehensive review of 1,402 partici-
pants with VCFS (age = 6-68 years), Schneider et al. (2014) 
reported that ADHD was the most frequent psychiatric dis-
order in children (37.1%) and among the most common in 
adults (15.6%). In contrast to the general population, where 
the combined type of ADHD is the most common, most 
cases of VCFS had the inattentive form of ADHD. A similar 
prevalence of ADHD was found in a smaller study by Tang 
et al. (2014), where 31% of 112 cases with VCFS (age = 
8-45 years, 37% ≥18 years) had ADHD, and 11% had psy-
chosis. There was no significant effect of age on the preva-
lence of ADHD in this group nor in a study by Niklasson 
et al. where in-depth neuropsychiatric assessments were 
done on 100 consecutive patients with VCFS (16% ≥17 
years; Niklasson, Rasmussen, Oskarsdottir, & Gillberg, 
2009). ADHD was diagnosed in 30 individuals; nine of 
these also had ASD. Gothelf et al. assessed 51 consecutive 
patients with VCFS, aged 16 to 30 years (Gothelf et al., 
2004). Twenty-one patients (41.2%) were diagnosed with 
ADHD (Mage [SD] = 11.1 [6.9]), and this group also had a 
significantly greater prevalence of ADHD among their first-
degree relatives. The authors concluded that ADHD in 
VCFS may have a genetic contribution, and that the VCFS-
related developmental factors might play a lesser role.
Both children and adults with trisomy 21 (Down’s syn-
drome; ICD-10: Q 90; Capone, Goyal, Ares, & Lannigan, 
2006; Edvardson et al., 2014) and fragile X syndrome 
(FXS; ICD-10: Q 99.2; Dorn, Mazzocco, & Hagerman, 
1994; Tranfaglia, 2011) have an increased prevalence of 
behavioral problems and comorbid diagnoses, including 
ADHD. FXS is the most common hereditary cause of intel-
lectual disability in men and also affects women. 
Hyperactivity symptoms in FXS usually decline with age 
(Tranfaglia, 2011). Unlike conventional X-linked disor-
ders, men can be carriers of the syndrome. These carriers 
(FXS premutation) may have normal intelligence but differ 
in response inhibition and selective attention, neuropsychi-
atric symptoms also found in ADHD (Cornish et al., 2008; 
Dorn et al., 1994). With age, individuals with FXS premu-
tation may develop more severe problems with inhibitory 
control. A small study from 1994 using a family informant 
method on 24 daughters of FXS carrier fathers and 32 
daughters of control fathers found a significantly higher 
proportion of aADHD as well as other psychopathology 
among FXS carrier fathers (Dorn et al., 1994). It has been 
proposed to screen for FXS carrier status in ADHD indi-
viduals whose male family members have intellectual dis-
ability (Hay, 2008).
As opposed to the mentioned chromosomal aberrations, 
only hyperactivity symptoms associated with ADHD were 
found more frequently in Angelman syndrome (ICD-10: 
Q93.5) when compared with a similar control group of indi-
viduals with intellectual disability (Berry, Leitner, Clarke, 
& Einfeld, 2005). Cornelia de Lange syndrome (CdLS; 
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Table 2. Other Comorbid Disorders With Limited Information on the Association With aADHD.
Comorbid disorder Reference Design Study population Result
STD Hosain, Berenson, 
Tennen, Bauer, & Wu 
(2012)
Cross-sectional 462 females (between 18 and 30 years). ASRS 
to assess ADHD symptoms. Self-reported 
lifetime diagnosis of STD.
aNo significant 
association
Cancer Bijlenga, van der Heijden, 
et al. (2013)
Case control 202 clinically assessed aADHD patients  
(Mage = 34.9), 189 controls (Mage = 33.0).
No significant 
association
Cancer Semeijn et al. (2013) Case control 23 participants with aADHD assessed by 
semistructured diagnostic interview (mean 
age 72.0), 208 controls (mean age 68.0).
No significant 
association
Congenitalesotropia Olson, Louwagie, Diehl, & 
Mohney, (2012)
Case control 42 congenitalesotropia patients, 20 controls.
Age at ADHD diagnosis not specified
No significant 
association
Photophobia Kooij & Bijlenga, (2014) Online survey 231 people with self-reported ADHD 
diagnosis/ADHD symptoms (mean age 36.7), 
263 controls (mean age 38.4).
Significant 
association
Note. aADHD = Adult ADHD; STD = sexually transmitted diseases.
a10% increased risk of being diagnosed with STD when comparing the ADHD symptom group with the control group, no longer statistically significant 
when adjusting for sociodemographic covariates.
ICD-10: Q87.1) is a very rare genetic disorder usually 
caused by de novo mutations. In their study of 69 CdLS 
patients, Kline et al. (2007) have described their physical 
and psychiatric disturbances, among which ADHD is one of 
several psychiatric diagnoses where the symptoms often 
worsen with age.
Regarding ADHD and comorbid anatomical anomalies 
that are not part of a well-known syndrome, there are few 
studies in adults. A large registry-based study from 2012 
found an increased risk of ADHD persisting to adulthood in 
individuals born with oral clefts (ICD-10: Q 35-37; Halmoy, 
Klungsoyr, Skjaerven, & Haavik, 2012). Another study 
describing 447 adults with Fallot’s tetralogy (TOF) found 
an increased prevalence of ADHD among TOF patients 
who had at least two additional “syndromic” features such 
as dysmorphic facies, learning disabilities, or voice abnor-
malities (Piran et al., 2011).
Enuresis (ICD-10: R32)
The previously described study by Bijlenga et al. showed 
no differences in self-reported urinary symptoms in people 
with aADHD and controls (Bijlenga, van der Heijden, et al., 
2013).
The diagnosis of enuresis in aADHD compared with 
controls is reported in two studies using information from 
U.S. claim databases. One study included 2,252 individuals 
diagnosed with ADHD according to ICD-9 during 1999-
2001 matched with a similar number of controls (Secnik 
et al., 2005). Based on ICD-9 codes, there was no signifi-
cant difference in the prevalence of enuresis between the 
groups. In a study investigating U.S. health care claims for 
2006 (aADHD: 31,752; non-ADHD: 95,256), adults with 
ADHD were significantly more often diagnosed with 
enuresis compared with adults without ADHD (p < .05; 
Hodgkins et al., 2011).
In a French study including 1,171 adults, ASRS was 
used to measure aADHD. aADHD was significantly related 
to lifetime self-reported enuresis regardless of sex, OR = 
5.8 [2.4, 14.1] (Caci et al., 2014).
Other Disorders
Our search also identified some papers describing various 
other disorders, summarized in Table 2. For most of these 
disorders, no significant association with aADHD was 
reported. The exception was for photophobia, where 69% of 
the ADHD participants reported photophobia compared 
with 28% in the control group (p = .001; Kooij & Bijlenga, 
2014).
Discussion
In our systematic review, we have included 126 papers over 
the past 20 years mentioning aADHD in connection with 
somatic disease. We found a consistent association between 
aADHD and increased risk of obesity, sleep disorders, and 
asthma. Associations were also consistent for migraine and 
celiac disease. Less robust associations have been reported for 
a number of different disorders such as enuresis, irritable 
bowel syndrome, restless legs, epilepsy, chronic fatigue syn-
drome, , fibromyalgic syndrome, systemic lupus erythemato-
sus and atopic dermatitis. One large population-based study 
(aADHD: n = 31,752) and two smaller studies showed no 
association between aADHD and diseases of the circulatory 
system (Hodgkins et al., 2011; Semeijn et al., 2013; Spencer 
et al., 2014). In contrast, a small study by Bijlenga et al. showed 
an increased risk of self-reported cardiovascular disorder in 
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aADHD. Many rare congenital syndromes/malformations, 
including tuberous sclerosis and FXS, are reported to increase 
the risk of ADHD. However, under such conditions the ADHD 
symptoms may also be considered part of the syndrome itself 
and not a proper comorbid disorder.
We noticed several methodological limitations in the 
evaluated studies. Most studies were small. Many studies 
compared a case group with a control/comparison group. 
However, while the case group might be well defined and 
characterized, the control group was often less well defined, 
often based on self-selection and from a different source 
population than the cases. Information on recruitment and 
participation rates was sparse, and selection bias was diffi-
cult to assess. While the diagnosis of ADHD was often 
based on clinical interviews or validated self-report ques-
tionnaires, the comorbid conditions were sometimes based 
entirely on a single question to the individual about the con-
dition being present or not. An example is the study by 
Bijlenga et al., which includes 202 clinically diagnosed 
ADHD patients and 189 controls non-randomly recruited 
from students and their acquaintances, and self-selected by 
posters in libraries and municipal buildings (Bijlenga, van 
der Heijden, et al., 2013). The numerous somatic diseases 
described were based solely on self-report from a general 
health questionnaire.
The larger studies were often based entirely on self-
report questionnaires or on registries and databases. Large 
population-based disease registries may be more suitable to 
study comorbidity across many different diagnoses, in par-
ticular for less prevalent conditions. However, such regis-
tries can also be subject to systematic bias, depending on 
the diagnostic traditions in different countries (Polanczyk 
et al., 2007) and the covered population.
For details on characteristics of the individual studies 
with their associated sources of bias, see table in 
Supplementary 2.
Many studies on psychiatric comorbidity in somatic con-
ditions have explicitly excluded “childhood” psychiatric 
conditions such as ADHD, as they are not included in com-
monly used structured psychiatric diagnostic interviews, 
such as The Structured Clinical Interview for DSM-IV Axis 
I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams, 
2002) or The Mini-International Neuropsychiatric Interview 
(MINI; Sheehan et al., 1998). This systematic bias could 
give the false impression that ADHD is not a relevant psy-
chiatric comorbidity in somatic disease among adults.
As mentioned in many of the cited articles, there are 
many reasons to systematically search for psychiatric disor-
ders in somatic conditions and to screen for somatic dis-
eases among psychiatric patients. For the individual patient, 
it is important to detect potentially treatable somatic dis-
eases masking as a psychiatric disorder. The utility of this 
approach was illustrated in a recent report, showing that 
metabolic screening of individuals with psychosis revealed 
treatable metabolic disorders in a significant number of 
cases (Demily & Sedel, 2014).
ADHD is a prevalent condition, and patients with many 
different somatic conditions may exhibit ADHD symptoms 
either as a comorbid condition or as part of the somatic dis-
ease. Likewise, the lifestyle of ADHD patients may make 
them more vulnerable to certain somatic diseases. Thus, the 
identification of other treatable and possibly underlying 
conditions should be addressed in every diagnostic workup.
The presence of a known co-occurring somatic condition 
has important implications for ADHD treatment. For 
instance, stimulant therapy may be contraindicated or need 
careful monitoring in the presence of cardiac disease, 
hypertension, glaucoma, or liver failure (Kooij, 2012). 
However, stimulant therapy may have positive effects on 
the treatment of obesity, sleep disorders, CFS, and restless 
legs.
Pathophysiology
Conditions classically thought to be disorders of the ner-
vous system may also include alterations in other physio-
logical systems, for example, involving immunological or 
endocrine signaling mechanisms (Qureshi & Mehler, 2013). 
Classical quantitative genetic studies, such as twin studies, 
and more recently genome-wide association studies with 
polygenic analyses have revealed genetic correlations 
between many different psychiatric and somatic disorders 
and traits. Elucidation of such shared genetic mechanism 
could lead to new therapies or diagnostic procedures. There 
is increasing evidence for inflammatory and autoimmune 
mechanisms in psychiatric disorders, including ADHD. In a 
recent epidemiological study of 48,000 Norwegian ADHD 
patients, a strong connection between immunological dis-
eases in the mothers and ADHD in the offspring was 
observed (Instanes et al., 2015).
Different hypotheses regarding underlying pathophysio-
logical mechanisms are further elaborated for some of the 
most commonly associated diseases.
Several mechanisms may account for the reported asso-
ciation between ADHD and obesity. Shared neurobiological 
or genetic mechanisms may be common to both ADHD and 
obesity (Nigg, 2013); ADHD and obesity being facets of the 
same underlying condition (Odent, 2010). Both ADHD and 
obesity are related to the dopamine system, and dopamine-
related genes may affect body weight, eating patterns, and 
ADHD (Davis, 2009). It has been hypothesized that the 
urge for food intake can share the same mechanisms as 
ADHD-drug abuse (Cortese et al., 2007; Davis, 2010). Low 
tonic dopamine levels in the prefrontal cortex may lead to 
overeating as a kind of self-medication to increase the dopa-
mine levels (Campbell & Eisenberg, 2007). Hypersensitivity 
to reward contributes to overeating because of an increased 
motivation in engaging in pleasurable activities (Davis, 
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2009). Other possible mechanisms involve the Brain 
Derived Neurotrophic Factor (Cortese & Morcillo-Peñalver, 
2010), immune or inflammatory response (Nigg, 2013), and 
the melatonin system (Cortese & Morcillo-Peñalver, 2010; 
Kirov & Brand, 2014). A mediation analysis conducted in a 
clinical sample including 114 obese people, 202 aADHD 
patients, and 154 controls showed that both sleep duration 
and unstable eating patterns mediated the association 
between BMI and ADHD after controlling for current anxi-
ety/depression and sociodemographics (Vogel et al., 2015).
Obesity and disorders related to obesity could also create 
symptoms resembling ADHD symptoms, such as sleep-
disordered breathing, which can lead to inattentive symp-
toms during the day (Cortese & Morcillo-Peñalver, 2010). 
ADHD itself can lead to obesity rather than the other way 
around (Cortese, Ramos-Olazagasti, et al., 2013). The 
behavior associated with ADHD can lead to bad eating hab-
its due to poor planning of the meals (Davis, 2009), or defi-
cient inhibitory control or aversion to delay leading to 
increased consumption of palatable fast food (Cortese, 
Angriman, et al., 2008; Davis et al., 2006). Impulsivity 
associated with binge eating may contribute to impulsivity 
as a symptom of ADHD in obese patients, and abnormal 
eating behaviors may lead to symptoms of inattention and 
hyperactivity (Cortese, Angriman, et al., 2008). ADHD may 
also be characterized by motor clumsiness and poor energy 
regulation, resulting in periods of overactivity interspersed 
with underactivity, making it difficult for persons with 
ADHD to be a part of activities promoting fitness and 
weight loss that requires planning and sustained effort 
(Nigg, 2013). Positive correlations between symptoms of 
aADHD measured by ASRS, depression, anxiety, and dis-
ordered eating pattern have been shown (Alfonsson et al., 
2012).
The cause of sleep problems in ADHD appears to be mul-
tifactorial and complex (Kirov & Brand, 2014), and the 
association between ADHD and sleep problems may be 
caused by different underlying pathways. It is not fully 
understood how obstructive sleep apnea, periodic limb 
movements during sleep, and RLS are connected to ADHD 
pathophysiology, or whether they can be viewed as comor-
bid sleep disorders in ADHD (Kirov & Brand, 2014). RLS 
share features with ADHD, and RLS and ADHD may be a 
part of the same symptom complex and share a central ner-
vous dopaminergic dysfunction (Philipsen, Hornyak, & 
Riemann, 2006). As for ADHD, altered dopaminergic sig-
naling and iron deficiency have been hypothesized to con-
tribute to the pathophysiology of RLS (Cortese et al., 2005; 
Cortese, Lecendreux, et al., 2008). Hyperactive symptoms 
may directly cause sleep problems (Hvolby, 2015), and per-
sons with ADHD can be more vulnerable to the effects of 
sleep disturbances (Hvolby, 2015). In itself, sleep problems 
may mimic ADHD symptomatology (Hvolby, 2015) and 
may also exacerbate underlying ADHD symptoms (Owens, 
2005). Insomnia may cause inattention, a core symptom of 
ADHD (Voinescu et al., 2012). Without a thorough assess-
ment, persons with sleep problems could be misdiagnosed as 
having ADHD (Gau et al., 2007). Furthermore, the stimulant 
treatment used for ADHD may result in sleep problems as a 
side effect (Owens, 2005). Common pathophysiology can 
lead to both ADHD and sleep disturbance (Brown & 
McMullen, 2001; Hvolby, 2015). Furthermore, a person 
with a delayed circadian rhythm may compensate being 
tired by binge eating during the day, which again leads to 
obesity (. Kooij & Bijlenga, 2013). A delayed sleep phase 
and sleep deficit can be risk factors for several disorders 
such as obesity, diabetes, and cardiovascular disorders 
(Kooij & Bijlenga, 2013).
As for ADHD, the dopaminergic system has also been 
suggested as a possible factor involved in the pathophysiol-
ogy of asthma, as dopaminergic receptors are present in 
sensory nerves in the airways, and inhaled dopamine may 
induce bronchodilation during asthma attacks (Birrell et al., 
2002; Cabezas, Lezama, & Velasco, 2001). Other common 
pathophysiological factors for these disorders may be 
inflammatory mechanisms (Barrios, Kheradmand, Batts, & 
Corry, 2006) and obesity (Cortese, Angriman, et al., 2008; 
Delgado, Barranco, & Quirce, 2008), as obesity leads to a 
proinflammatory state (Bazar, Yun, Lee, Daniel, & Doux, 
2006).
There is substantial evidence that dopaminergic mecha-
nisms are involved in migraine. It is therefore possible that 
changes in dopaminergic systems may represent common 
etiological factors for ADHD and migraine (Fasmer, 
Akiskal, Kelsoe, & Oedegaard, 2009).
Suggestions for Further Research
A number of shortcomings have been identified in the lit-
erature cited in this review.
1. Different research designs have been utilized to 
explore the relationship between ADHD and somatic 
health. As each of these designs has their inherent 
limitations, there is a need to establish the preva-
lence of somatic diseases in representative samples 
of ADHD.
2. In many studies, the patients were simply screened 
for ADHD symptoms. We need to know what pro-
portion of these patients has the full clinical syn-
drome, including impairment criteria. Harmonization 
of diagnostic protocols should increase reliability of 
such data.
3. It is suspected that many of the reported associated 
conditions are due to recognized or previously 
unknown confounders. Future research should 
investigate how much of the comorbidities are actu-
ally due to confounding factors, for example, that 
Instanes et al. 19
headache or sleep disorders may be confounding 
factors for the association between obesity and 
ADHD (Cortese & Angriman, 2014; Gau et al., 
2007), or that iron deficiency in ADHD is explained 
by, at least partly, the elevated presence of obesity 
(Cortese & Angriman, 2014).
4. Many of the existing studies are small. To be able to 
reveal a true association between ADHD and comor-
bid somatic diseases with adequate control for 
potential confounders, large studies are needed. The 
possibilities of combining the use of population-
based registries and common diagnostic protocols 
should be investigated.
5. From a practical perspective, we need to know how 
current diagnostic and treatment algorithms should 
be optimized to account for coexisting conditions.
6. Access to biomarkers from large samples of ADHD 
cases and its comorbid conditions will allow sys-
tematic studies of their shared pathophysiology. 
This information should also inform future deci-
sions regarding diagnoses and treatment.
7. Even for the best documented conditions, the litera-
ture was dominated by a few authors, research 
groups, and study populations. More research 
should be conducted in different geographical areas 
and ethnic groups.
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